aliard
use
nanotechnolog
end
identifi
sever
potenti
target
propos
deliveri
agent
use
nanomicel
improv
drug
deliveri
recent
year
nanomedicin
becom
attract
concept
target
deliveri
therapeut
diagnost
compound
lung
dame
et
al
foldvari
elsabahi
nanoscal
drug
deliveri
system
abil
improv
pharmacokinet
increas
biodistribut
therapeut
agent
target
organ
therebi
result
improv
efficaci
reduc
drug
toxic
kim
et
al
koo
et
al
singh
nanocarri
particularli
design
target
inflamm
cancer
permeabl
vasculatur
among
variou
drug
deliveri
system
consid
pulmonari
applic
use
biodegrad
polymer
nanoparticl
repres
sever
advantag
treatment
respiratori
diseas
bailey
berkland
buxton
number
differ
strategi
propos
modif
nanoparticl
characterist
control
behavior
within
biolog
environ
like
cellspecif
target
drug
deliveri
modifi
biolog
distribut
drug
cellular
organ
level
method
deliveri
particularli
attract
inflammatori
condit
acut
lung
injuri
ali
acut
respiratori
distress
syndrom
ard
despit
recent
advanc
diagnost
therapeut
modal
ali
ard
still
repres
unmet
medic
need
associ
appreci
morbid
mortal
substanti
medic
expenditur
girard
bernard
matthay
matthay
ware
rubenfeld
herridg
henc
urgent
need
develop
test
new
drug
treat
devast
disord
unfortun
contemporari
drug
develop
approach
address
challeng
center
monometabol
pathway
inhibitor
hinder
divers
mechan
underli
ali
ard
pathogenesi
nonselect
drug
effect
could
predispos
seriou
advers
event
overcom
barrier
emul
clinic
success
combin
therapi
cancer
hiv
shey
et
al
devis
innov
nanopharmacotherapeut
strategi
consist
combin
three
longact
safe
nanomedicin
select
target
inhibit
three
distinct
key
intracellular
proinflammatori
signal
cascad
activ
ali
accordingli
har
uniqu
attribut
three
novel
longact
biocompat
biodegrad
antiinflammatori
nanomedicin
consist
two
amphipath
peptid
drug
human
glucagonlik
amid
trigger
receptor
express
myeloid
cell
peptid
waterinsolubl
cytotox
drug
innov
approach
consist
selfassembl
drug
us
fdagener
regard
safe
gra
distearoylphosphatidylethanolamin
coval
link
polyethylen
glycol
molecular
weight
dspepeg
compon
usfdaapprov
doxil
form
longact
biocompat
biodegrad
steric
stabil
phospholipid
nanomicel
ssm
aqueou
milieu
size
nm
rubinstein
b
sadikot
et
al
sadikot
et
al
b
ssm
novel
longact
biocompat
biodegrad
phospholipidbas
drug
deliveri
vehicl
act
versatil
carrier
platform
peptid
waterinsolubl
drug
approach
entail
selfassembl
distearoylphosphatidylethanolamin
coval
link
polyethylen
glycol
molecular
weight
dspepeg
drug
form
ssm
aqueou
milieu
size
nm
diamet
koo
et
al
nanomicel
compos
hydrophil
corona
hous
amphipath
peptid
drug
peptid
hydrophob
core
accommod
waterinsolubl
drug
simpl
prepar
unlik
liposom
store
lyophil
form
without
lyoor
cryoprotect
extend
period
time
nanomicel
stabil
peptid
activ
biolog
form
ahelix
prefer
ligandreceptor
interact
prevent
rapid
peptid
degrad
vivo
therebi
prolong
bioactiv
alsabah
donnelli
alana
et
al
addit
ssm
solubil
high
concentr
unlik
surfact
micel
low
critic
micellar
concentr
mm
nanoparticl
prevent
disintegr
upon
dilut
biolog
fluid
importantli
peg
moieti
ssm
confer
steric
hindranc
circul
nanos
mitig
renal
clearanc
extravas
intact
microvessel
turn
prolong
circul
time
drugload
nanomicel
promot
preferenti
extravas
hyperperm
lung
microcircul
hallmark
ali
injur
lung
innov
passiv
target
therapeut
strategi
amplifi
drug
deliveri
lung
therebi
maxim
efficaci
enhanc
resolut
inflamm
reduc
collater
damag
innoc
bystand
organ
nanomicel
fdaapprov
human
studi
lim
et
al
system
deliveri
nanoparticl
base
principl
passiv
target
passiv
target
occur
result
extravas
nanoparticl
diseas
site
microvasculatur
leaki
pison
et
al
exampl
diseas
passiv
target
nanocarri
achiev
tumor
inflam
tissu
microvascular
leaki
ali
ard
result
increas
permeabl
presenc
cytokin
vasoact
factor
enhanc
permeabl
matthay
ware
thu
drug
use
treatment
ali
ard
administ
system
local
lung
passiv
target
innov
passiv
target
therapeut
strategi
amplifi
drug
deliveri
lung
therebi
maxim
efficaci
enhanc
resolut
inflamm
reduc
collater
damag
innoc
bystand
organ
occur
patient
ali
ard
among
variou
drug
deliveri
system
consid
pulmonari
applic
nanoparticl
demonstr
sever
advantag
treatment
respiratori
diseas
includ
prolong
drug
releas
cellspecif
target
drug
deliveri
modifi
biolog
distribut
drug
cellular
organ
level
azarrmi
et
al
roy
vij
rudolph
et
al
yang
et
al
nanoparticl
compos
biodegrad
lipidbas
nanomicel
polym
fulfil
mani
requir
place
deliveri
system
abil
transfer
aerosol
stabil
forc
gener
aerosol
biocompat
target
specif
site
cell
popul
lung
releas
drug
predetermin
manner
degrad
within
accept
period
time
roy
vij
yacobi
et
al
clearli
studi
warrant
establish
role
aerosol
nanoprepar
inhal
therapi
use
nanomicellar
prepar
deliveri
target
drug
lung
use
system
approach
micel
selfassembl
amphiphil
form
supramolecular
coreshel
structur
aqueou
environ
koo
et
al
hydrophob
interact
predomin
drive
forc
assembl
amphiphil
aqueou
medium
concentr
exceed
cmc
ssm
develop
patent
laboratori
versatil
carrier
peptid
waterinsolubl
drug
rubinstein
b
sadikot
et
al
sadikot
et
al
b
system
deliveri
agent
base
principl
passiv
target
kim
et
al
koo
et
al
passiv
target
occur
due
extravas
nanoparticl
diseas
site
microvasculatur
leaki
liu
et
al
exampl
diseas
passiv
target
nanocarri
achiev
tumor
inflam
tissu
leaki
aliard
result
increas
permeabl
presenc
cytokin
vasoact
factor
enhanc
permeabl
thu
agent
use
treatment
aliard
administ
system
local
lung
passiv
target
hypothes
innov
passiv
target
therapeut
strategi
amplifi
drug
deliveri
lung
therebi
maxim
efficaci
enhanc
resolut
inflamm
reduc
collater
damag
innoc
bystand
organ
occur
patient
sepsi
ard
control
drug
deliveri
system
also
becom
increasingli
attract
option
inhal
therapi
klingler
et
al
mansour
et
al
roy
vij
larg
surfac
area
lung
minim
barrier
imped
access
lung
peripheri
make
organ
suitabl
portal
varieti
therapeut
intervent
beckbroichsitt
et
al
bur
et
al
buxton
bloodbarri
alveolar
space
pulmonari
capillari
thin
allow
rapid
ga
exchang
alveoli
small
approxim
million
lung
although
alveoli
tini
structur
larg
surfac
area
total
perform
effici
ga
exchang
make
attract
organ
direct
drug
deliveri
rudolph
et
al
smola
et
al
among
variou
drug
deliveri
system
consid
pulmonari
applic
nanoparticl
demonstr
sever
advantag
treatment
respiratori
diseas
prolong
drug
releas
cellspecif
target
drug
deliveri
modifi
biolog
distribut
drug
cellular
organ
level
azarrmi
et
al
bailey
berkland
pison
et
al
sung
et
al
yang
et
al
nanoparticl
compos
biodegrad
polym
fulfil
mani
requir
place
deliveri
system
abil
transfer
aerosol
stabil
forc
gener
aerosol
biocompat
target
specif
site
cell
popul
lung
releas
drug
predetermin
manner
degrad
within
accept
period
time
ryt
et
al
schleh
et
al
yacobi
et
al
studi
need
establish
role
aerosol
nanoprepar
inhal
therapi
ali
ard
aris
direct
indirect
injuri
lung
result
lifethreaten
form
respiratori
failur
diffus
bilater
lung
injuri
sever
hypoxemia
caus
noncardiogen
pulmonari
edema
affect
approxim
million
peopl
worldwid
annual
girard
bernard
rubenfeld
herridg
inflammatori
process
elsewher
bodi
lung
inflamm
accompani
mani
cellular
biochem
process
specif
syndrom
includ
injuri
pulmonari
capillari
endothelium
alveolar
epithelium
import
ali
highlight
emerg
sar
sever
acut
respiratori
syndrom
ali
ard
lead
caus
morbid
mortal
unit
state
matthay
ware
major
reason
underli
lag
improv
outcom
lack
novel
specif
therapi
ali
ard
matthay
thu
ard
repres
unmet
medic
need
urgent
need
develop
novel
therapi
condit
molecular
pathobiolog
ard
extens
defin
role
sever
molecul
includ
pattern
recognit
receptor
present
immun
cell
tolllik
receptor
downstream
signal
molecul
nfkb
effector
molecul
tnfa
investig
pathogenesi
treatment
ali
ard
target
central
molecul
nfkb
attenu
lung
inflamm
major
limit
inhibit
nfkb
immunosuppress
compromis
host
defens
sadikot
et
al
howev
complex
natur
diseas
target
singl
cytokin
chemokin
also
fail
attenu
lung
inflamm
suffici
singli
attenu
lung
inflamm
ard
thu
propos
innov
approach
involv
target
multipl
upstream
molecul
bouchon
et
al
bouchon
et
al
reactiv
oxygen
speci
ro
lead
activ
nfkb
ultim
lead
ali
ard
poor
outcom
mani
case
develop
novel
approach
deliv
inhibitor
molecul
vivo
previous
shown
individu
nanoformul
effect
attenu
lung
inflamm
use
combin
therapeut
approach
involv
three
distinct
intracellular
metabol
pathway
like
success
patient
cancer
sadikot
et
al
nanoparticl
potenti
applic
medic
field
includ
diagnost
therapeut
nanoscal
drug
deliveri
system
abil
improv
pharmacokinet
increas
biodistribut
therapeut
agent
target
organ
result
improv
efficaci
reduc
drug
toxic
koo
et
al
rudolph
et
al
nanocarri
particularli
design
target
inflamm
cancer
permeabl
vasculatur
addit
mani
nanocarri
desir
advantag
improv
solubl
hydrophob
compound
aqueou
media
render
suitabl
parenter
administr
particular
deliveri
system
shown
increas
stabil
wide
varieti
therapeut
agent
hydrophob
molecul
peptid
oliginucleotid
koo
et
al
system
exploit
diagnost
therapeut
purpos
carri
drug
bodi
control
manner
site
administr
therapeut
target
mazzon
impli
passag
drug
molecul
drug
deliveri
system
across
numer
physiolog
barrier
repres
challeng
goal
drug
target
nanoparticl
construct
variou
methodolog
effect
target
desir
site
koo
et
al
begin
address
potenti
nanotechnolog
treatment
ard
develop
novel
longact
biocompat
biodegrad
phospholipid
micel
size
nm
modul
key
signal
molecul
critic
inflammatori
respons
ali
ard
matthay
ware
select
molecul
initi
propag
inflammatori
respons
distinct
mechan
multipl
pathway
target
either
singli
combinatori
approach
diseas
like
hiv
shey
et
al
among
bouchon
et
al
bouchon
et
al
ro
initi
select
modul
inflammatori
respons
lung
sadikot
et
al
sadikot
et
al
realiz
short
halflif
peptid
drug
min
hamper
clinic
use
invent
micellar
peptid
peptid
drug
stabil
activ
form
ahelix
bioactiv
prolong
hour
vivo
likewis
waterinsolubl
select
inhibitor
constrain
use
human
accordingli
selfassoci
micel
overcom
limit
time
increas
stabil
bioavail
longact
micellar
drug
provid
signific
advanc
treatment
experiment
ali
could
extend
critic
ill
patient
nanoparticl
introduc
system
administr
oral
dermal
intraven
etc
directli
introduc
lung
inhal
intranas
oropharyng
aspir
recent
studi
test
efficaci
nanomicel
mous
model
lipopolysaccharid
lp
induc
lung
injuri
lim
et
al
sadikot
et
al
b
vivo
administr
lpsinduc
ali
mice
result
signific
downregul
lung
inflamm
dosedepend
antiinflammatori
activ
observ
similar
therapeut
activ
detect
salin
indic
ssm
nanocarri
play
critic
role
protect
enzymelabil
deliv
inflam
tissu
vivo
studi
demonstr
first
time
lipidbas
nanoformul
effect
attenu
inflamm
aliard
lim
et
al
also
test
efficaci
nanomicel
peptid
model
lpsinduc
sepsi
lung
injuri
shown
nanomicel
efficaci
nake
peptid
abrog
inflamm
sadikot
et
al
b
studi
nanomicel
prepar
treatment
aliard
current
ongo
laboratori
togeth
studi
demonstr
feasibl
translat
use
nanomicel
prepar
translat
human
studi
clinic
treat
devast
diseas
hypothes
combinatori
administr
nanomicel
modul
distinct
signal
pathway
prove
potent
howev
need
studi
optim
administr
nanoprepar
nanotechnolog
emerg
scienc
involv
manipul
materi
nanomet
scale
nanomedicin
medic
applic
nanotechnolog
promis
endless
rang
applic
biomed
imag
drug
deliveri
therapeut
novel
approach
use
nanotechnolog
revolution
futur
medicin
advanc
nanotechnolog
prove
benefici
therapeut
field
drug
discoveri
drug
deliveri
geneprotein
deliveri
nanoparticul
drug
deliveri
system
design
multifunct
engin
nanoparticl
appear
particularli
attract
promis
drug
deliveri
organ
lung
sinc
combin
sever
opportun
like
uniform
distribut
drug
dose
among
ventil
alveoli
allow
uniform
cellular
drug
intern
besid
sustain
releas
drug
plasma
organ
potenti
advantag
system
includ
possibl
reduct
drug
dosag
advers
effect
drug
interact
although
field
nanomedicin
offer
multipl
opportun
still
infanc
research
proceed
order
obtain
specif
target
drug
combin
minimum
side
effect
ongo
studi
offer
sever
excit
prospect
applic
engin
nanomateri
drug
deliveri
year
come
